SYK Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

7.12B

+10.57%

4.391

+9.51%

6.32B

+7.74%

3.063

+7.86%

6.54B

+8.64%

3.477

+11.1%

Estimates Revision

The market is revising Upward the revenue expectations for Stryker Corporation (SYK) for FY2025, with the revenue forecasts being adjusted by 0.25% over the past three months. During the same period, the stock price has changed by -6.59%.

Revenue Estimates for FY2025

Revise Upward

+0.25%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.39%

In Past 3 Month

Stock Price

Go Down

-6.59%

In Past 3 Month

18 Analyst Rating

Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is 432.38 USD with a low forecast of 400.00 USD and a high forecast of 456.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

3 Hold

0 Sell

Strong Buy

Current: 352.270

Low

400.00

Averages

432.38

High

456.00

Current: 352.270

Low

400.00

Averages

432.38

High

456.00

Citi

Joanne Wuensch

Buy

downgrade

$455 -> $420

2025-12-11

New

Reason

Citi

Joanne Wuensch

Price Target

$455 -> $420

2025-12-11

New

downgrade

Buy

Reason

Citi analyst Joanne Wuensch lowered the firm's price target on Stryker to $420 from $455 and keeps a Buy rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.

Truist

Richard Newitter

Hold

maintain

$392 -> $400

2025-11-14

Reason

Truist

Richard Newitter

Price Target

$392 -> $400

2025-11-14

maintain

Hold

Reason

Truist analyst Richard Newitter raised the firm's price target on Stryker to $400 from $392 and keeps a Hold rating on the shares. The company's Investor Day showcased why Stryker should remain one of the higher quality large-cap MedTechs with "muscle" and continue delivering annual operating leverage, the analyst tells investors in a research note. Truist adds however that it remains in neutral as the firm prefers large-caps with faster earnings and revenue growth profiles.

Wells Fargo

Overweight

maintain

$452 -> $456

2025-11-14

Reason

Wells Fargo

Price Target

$452 -> $456

2025-11-14

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Stryker to $456 from $452 and keeps an Overweight rating on the shares. The firm notes the company's 2025 investor meeting highlighted the potential for sustained 10% organic topline growth and double-digit EPS growth. Margin target of 150bps next 3 years was slightly better than expected. Key pipeline updates include Mako RPS hand-held robot, Wells adds.

BTIG

Buy

downgrade

$122 -> $112

2025-11-05

Reason

BTIG

Price Target

$122 -> $112

2025-11-05

downgrade

Buy

Reason

BTIG lowered the firm's price target on Zimmer Biomet (ZBH) to $112 from $122 and keeps a Buy rating on the shares following disappointing Q3 results. The firm notes that relative to peers, Zimmer Knee growth fell below Stryker (SYK) but above Johnson & Johnson (JNJ) while Hips were softest among the 3. There is no way to spin it, results were disappointing relative to expectations as Zimmer came off a strong Q2 and into the print investor enthusiasm was growing from an easier comp and new product launches, says BTIG.

Truist

Hold

downgrade

$407 -> $392

2025-11-03

Reason

Truist

Price Target

$407 -> $392

2025-11-03

downgrade

Hold

Reason

Truist lowered the firm's price target on Stryker to $392 from $407 and keeps a Hold rating on the shares. The company delivered a small revenue beat with mixed quality earnings upside that was driven by non-op items and tax, which offset a slight operating margin miss, the analyst tells investors in a research note.

Evercore ISI

Outperform

maintain

$410 -> $405

2025-10-31

Reason

Evercore ISI

Price Target

$410 -> $405

2025-10-31

maintain

Outperform

Reason

Evercore ISI lowered the firm's price target on Stryker to $405 from $410 and keeps an Outperform rating on the shares. Stryker's Q3 performance was solid with a 9.5% organic growth, slightly topping Wall Street estimates, mainly driven by Orthopedics' strong showing, the analyst tells investors in a research note. The firm noted that MedSurg and NeuroTech held steady, though Endoscopy and Medical lagged a bit behind expectations.

Valuation Metrics

The current forward P/E ratio for Stryker Corp (SYK.N) is 24.41, compared to its 5-year average forward P/E of 26.33. For a more detailed relative valuation and DCF analysis to assess Stryker Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

26.33

Current PE

24.41

Overvalued PE

28.44

Undervalued PE

24.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

21.38

Current EV/EBITDA

19.87

Overvalued EV/EBITDA

22.88

Undervalued EV/EBITDA

19.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.35

Current PS

5.10

Overvalued PS

5.85

Undervalued PS

4.85

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 143.32% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 119.77% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 143.32% over the last month.

Sold

Bought

SYK News & Events

Events Timeline

No data

News

4.5

12-11NASDAQ.COM

ETF Outflow Warning for VV, BSX, DHR, SYK

8.0

12-11NASDAQ.COM

Daily Dividend Update: BMY, SYK, MDLZ, CL, MO

8.0

12-11Newsfilter

Stryker Increases Quarterly Dividend to $0.88 per Share

People Also Watch

Frequently Asked Questions

What is Stryker Corp (SYK) stock price today?

The current price of SYK is 352.27 USD — it has decreased -0.51 % in the last trading day.

What is Stryker Corp (SYK)'s business?

Stryker Corporation is a medical technology company. The Company offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The Company also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.

What is the price predicton of SYK Stock?

What is Stryker Corp (SYK)'s revenue for the last quarter?

Stryker Corp revenue for the last quarter amounts to 6.06B USD, increased 10.25 % YoY.

What is Stryker Corp (SYK)'s earnings per share (EPS) for the last quarter?

Stryker Corp. EPS for the last quarter amounts to 2.22 USD, increased 2.78 % YoY.

What changes have occurred in the market's expectations for Stryker Corp (SYK)'s fundamentals?

How many employees does Stryker Corp (SYK). have?

Stryker Corp (SYK) has 53000 emplpoyees as of December 15 2025.

What is Stryker Corp (SYK) market cap?

Today SYK has the market capitalization of 135.41B USD.